Literature DB >> 31846694

Mutant ACTB mRNA 3'-UTR promotes hepatocellular carcinoma development by regulating miR-1 and miR-29a.

Yong Li1, Hongbin Ma1, Changying Shi2, Feiling Feng3, Liang Yang4.   

Abstract

In recent years, studies demonstrate that ACTB has been found to be associated with various tumors. Although ACTB is dysregulated in numerous cancer types, limited data are available on the potential function and mechanism of ACTB in hepatocellular carcinoma (HCC). This study evaluated the expression and biological roles of mutant ACTB mRNA 3'-UTR in HCC. Transcriptome sequence and qRT-PCR analysis determined that mutant ACTB mRNA '-UTR was high expression in tumor tissues. Luciferase reporter assay showed that the ACTB mRNA 3'-UTR mutations made it easier to interact with miR-1 and miR-29a. Moreover, mutant ACTB mRNA '-UTR regulated miR-1 and miR-29a degradation via AGO2. Furthermore, mutant ACTB mRNA 3'-UTR promoted hepatocellular carcinoma cells migration and invasion in vitro and in vivo by up-regulating miR-1 target gene MET and miR-29a target gene MCL1. In a word, our study demonstrates that 3'-UTR of ACTB plays a key role in the development of hepatocellular carcinoma (HCC) and highlights the molecular mechanisms underlying such a complex process.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Hepatocellular carcinoma; Mutant ACTB mRNA 3′-UTR; miR-1; miR-29a

Mesh:

Substances:

Year:  2019        PMID: 31846694     DOI: 10.1016/j.cellsig.2019.109479

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  2 in total

1.  A pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers.

Authors:  Yuxi Gu; Shouyi Tang; Zhen Wang; Luyao Cai; Haosen Lian; Yingqiang Shen; Yu Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 2.  New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics.

Authors:  Ya-Ling Yang; Yen-Hsiang Chang; Chia-Jung Li; Ying-Hsien Huang; Ming-Chao Tsai; Pei-Yi Chu; Hung-Yu Lin
Journal:  J Pers Med       Date:  2021-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.